Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes
- 28 September 1999
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 96 (20) , 11000-11007
- https://doi.org/10.1073/pnas.96.20.11000
Abstract
Human rhinoviruses, the most important etiologic agents of the common cold, are messenger-active single-stranded monocistronic RNA viruses that have evolved a highly complex cascade of proteolytic processing events to control viral gene expression and replication. Most maturation cleavages within the precursor polyprotein are mediated by rhinovirus 3C protease (or its immediate precursor, 3CD), a cysteine protease with a trypsin-like polypeptide fold. High-resolution crystal structures of the enzyme from three viral serotypes have been used for the design and elaboration of 3C protease inhibitors representing different structural and chemical classes. Inhibitors having α,β-unsaturated carbonyl groups combined with peptidyl-binding elements specific for 3C protease undergo a Michael reaction mediated by nucleophilic addition of the enzyme’s catalytic Cys-147, resulting in covalent-bond formation and irreversible inactivation of the viral protease. Direct inhibition of 3C proteolytic activity in virally infected cells treated with these compounds can be inferred from dose-dependent accumulations of viral precursor polyproteins as determined by SDS/PAGE analysis of radiolabeled proteins. Cocrystal-structure-assisted optimization of 3C-protease-directed Michael acceptors has yielded molecules having extremely rapid in vitro inactivation of the viral protease, potent antiviral activity against multiple rhinovirus serotypes and low cellular toxicity. Recently, one compound in this series, AG7088, has entered clinical trials.Keywords
This publication has 34 references indexed in Scilit:
- Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amidesBioorganic & Medicinal Chemistry, 1999
- Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine ReplacementsJournal of Medicinal Chemistry, 1999
- Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure−Activity Studies of Ketomethylene-Containing PeptidomimeticsJournal of Medicinal Chemistry, 1999
- Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity StudiesJournal of Medicinal Chemistry, 1998
- Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure−Activity StudiesJournal of Medicinal Chemistry, 1998
- Refined X-ray crystallographic structure of the poliovirus 3C gene product 1 1Edited By D. ReesJournal of Molecular Biology, 1997
- Small peptidic aldehyde inhibitors of human rhinovirus 3C proteaseBioorganic & Medicinal Chemistry Letters, 1996
- Measurement of individual rate constants of irreversible inhibition of a cysteine proteinase by an epoxysuccinyl inhibitorBioorganic & Medicinal Chemistry Letters, 1995
- Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C proteaseBioorganic & Medicinal Chemistry Letters, 1995
- A consensus sequence for substrate hydrolysis by rhino virus 3C proteinaseFEBS Letters, 1989